Inogen, Inc (NASDAQ:INGN) Director Heath Lukatch sold 2,500 shares of Inogen stock in a transaction on Friday, December 1st. The stock was sold at an average price of $126.40, for a total value of $316,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Heath Lukatch also recently made the following trade(s):

  • On Wednesday, September 6th, Heath Lukatch sold 2,500 shares of Inogen stock. The stock was sold at an average price of $97.44, for a total value of $243,600.00.

Inogen, Inc (INGN) traded down $0.79 during midday trading on Tuesday, hitting $118.31. The stock had a trading volume of 150,074 shares, compared to its average volume of 171,878. Inogen, Inc has a 12 month low of $60.02 and a 12 month high of $130.05. The firm has a market capitalization of $2,460.00, a PE ratio of 99.99, a price-to-earnings-growth ratio of 5.17 and a beta of 1.13.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.04. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The company had revenue of $69.00 million during the quarter, compared to analysts’ expectations of $63.55 million. During the same period in the previous year, the firm posted $0.25 earnings per share. The business’s revenue for the quarter was up 26.8% compared to the same quarter last year. research analysts forecast that Inogen, Inc will post 1.19 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Schroder Investment Management Group acquired a new position in shares of Inogen in the second quarter worth $132,000. Ameritas Investment Partners Inc. raised its holdings in shares of Inogen by 6.1% in the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after acquiring an additional 86 shares during the last quarter. Sei Investments Co. raised its holdings in shares of Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after acquiring an additional 443 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Inogen by 17.8% in the second quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock worth $194,000 after acquiring an additional 307 shares during the last quarter. Finally, Pinebridge Investments L.P. raised its holdings in shares of Inogen by 1.6% in the second quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock worth $204,000 after acquiring an additional 33 shares during the last quarter.

Several equities analysts recently issued reports on INGN shares. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective for the company in a report on Thursday, November 9th. Needham & Company LLC lifted their price objective on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. BidaskClub raised Inogen from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 8th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $90.00 price objective on shares of Inogen in a report on Tuesday, September 12th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $120.00 price objective (up from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Four investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $103.14.

TRADEMARK VIOLATION NOTICE: This piece was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/05/inogen-inc-ingn-director-heath-lukatch-sells-2500-shares.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.